IMMUNOVANT ($IMVT) posted quarterly earnings results for Q3 2026 on Friday, February 6th. The company reported earnings of -$0.61 per share, beating estimates of -$0.73 by $0.12. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $IMVT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
IMMUNOVANT Insider Trading Activity
IMMUNOVANT insiders have traded $IMVT stock on the open market 16 times in the past 6 months. Of those trades, 1 have been purchases and 15 have been sales.
Here’s a breakdown of recent trading of $IMVT stock by insiders over the last 6 months:
- SCIENCES LTD. ROIVANT purchased 16,666,666 shares for an estimated $349,999,986
- ANDREW J. FROMKIN has made 0 purchases and 2 sales selling 22,249 shares for an estimated $517,189.
- DOUGLAS J. HUGHES has made 0 purchases and 2 sales selling 15,000 shares for an estimated $348,665.
- MELANIE GLORIA (Chief Operating Officer) has made 0 purchases and 2 sales selling 12,626 shares for an estimated $298,237.
- TUYL CHRISTOPHER VAN (Chief Legal Officer) has made 0 purchases and 2 sales selling 10,813 shares for an estimated $290,942.
- JAY S STOUT (Chief Technology Officer) has made 0 purchases and 5 sales selling 7,285 shares for an estimated $157,166.
- MICHAEL GEFFNER (Chief Medical Officer) has made 0 purchases and 2 sales selling 3,867 shares for an estimated $70,116.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
IMMUNOVANT Hedge Fund Activity
We have seen 104 institutional investors add shares of IMMUNOVANT stock to their portfolio, and 63 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 3,869,640 shares (-20.8%) from their portfolio in Q3 2025, for an estimated $62,378,596
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,714,258 shares (-24.9%) from their portfolio in Q3 2025, for an estimated $27,633,838
- ADAR1 CAPITAL MANAGEMENT, LLC added 1,706,687 shares (+319.0%) to their portfolio in Q3 2025, for an estimated $27,511,794
- VANGUARD GROUP INC added 952,504 shares (+14.0%) to their portfolio in Q4 2025, for an estimated $24,212,651
- JENNISON ASSOCIATES LLC added 700,464 shares (+inf%) to their portfolio in Q4 2025, for an estimated $17,805,794
- ARMISTICE CAPITAL, LLC added 636,000 shares (+12.2%) to their portfolio in Q3 2025, for an estimated $10,252,320
- PERCEPTIVE ADVISORS LLC removed 550,000 shares (-25.7%) from their portfolio in Q3 2025, for an estimated $8,866,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
IMMUNOVANT Analyst Ratings
Wall Street analysts have issued reports on $IMVT in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 09/30/2025
- B of A Securities issued a "Buy" rating on 08/12/2025
To track analyst ratings and price targets for IMMUNOVANT, check out Quiver Quantitative's $IMVT forecast page.
IMMUNOVANT Price Targets
Multiple analysts have issued price targets for $IMVT recently. We have seen 6 analysts offer price targets for $IMVT in the last 6 months, with a median target of $31.5.
Here are some recent targets:
- Danielle Brill from Truist Securities set a target price of $22.0 on 01/08/2026
- Andy Chen from Wolfe Research set a target price of $50.0 on 01/06/2026
- Corinne Johnson from Goldman Sachs set a target price of $28.0 on 12/15/2025
- Brian Cheng from JP Morgan set a target price of $33.0 on 09/30/2025
- Douglas Tsao from HC Wainwright & Co. set a target price of $35.0 on 09/04/2025
- Jason Gerberry from B of A Securities set a target price of $30.0 on 08/12/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
